Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that HER2-positive and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.

Citation

Anastrozole Monotherapy, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6358/254_v5_Anastrazole.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-11-01	Health Service Executive	Indication approved for reimbursement.